Safety and Immunogenicity Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged Years 3-60

Quadrivalent Influenza Virus Vaccine Clinical Trial

Status Enrolling by invitation

Clinical Trial Summary

This study evaluates the safety and immunogenicity of the quadrivalent influenza virus vaccine in healthy people aged years 3-60.Subjects will be randomly divided into 3 groups,receiving the test vaccine, commercially available trivalent influenza vaccine and trivalent influenza vaccine containing new influenza B component respectively. Each group has 800 subjects,2400 in total.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Quadrivalent Influenza Virus Vaccine

• NCT number: NCT02806804
• Study type: Interventional
• Source: Beijing Chaoyang District Centre for Disease Control and Prevention
• Status: Enrolling by invitation
• Phase: Phase 3
• Start date: May 2016